ERBB2 and cancer: In fact, chemotherapy (by further enhancing the expression of NK-activating ligands or reducing the expression of NK-inhibitory ligands on tumor cells) [151] and HER2-targeted therapy (by Trastuzumab-induced NK cell-based antibody-dependent cell-mediated cytotoxicity, i.e. ADCC) [152] were shown to increase cancer cell sensitivity to NK-mediated cytotoxicity which could act synergistically with the basal high expression of NK-activating ligands in basal-like and/or HER2-positive BCs.